## **BMO Partners Group Private Markets Fund**

Series F, CAD & USD Monthly Commentary

#### **Overview**

BMO Partners Group Private Markets Fund ("BMO PG Fund") provides single-ticket access to global diversified private markets for Canadian accredited investors. <sup>1</sup> It can act as a core, long-term building block for portfolios, complementing public market holdings and enhancing risk-reward.

## Why Invest?

- Simplified access: Single investment with dynamic, global access to all major private market asset classes
- A key complement to portfolios: A core, long-term investment that complements public market holdings with potential for reduced risk and improved returns
- Invest like an institution: Sophisticated investors, like major Canadian pension plans, have long benefitted from exposure to private markets
- Innovative evergreen structure: No capital calls, immediate exposure to private markets, and automatically reinvests distributions
- Investor-focused: Buy when you want and periodic ability to sell if you need (subject to redemption restrictions and early redemption fee)<sup>3</sup>, with lower minimum investment amounts in a registered plan eligible format, subject to certain conditions<sup>4</sup>
- A marquee collaboration: Partners Group, BMO PG Fund's portfolio manager, is a leading global private markets firm with US\$149Bn<sup>5</sup> AUM globally, including tier-one institutional investors

RRSP/RRIF/TFSA Eligibility	Yes (subject to certain conditions) <sup>4</sup>
Offering Document	Offering Memorandum
Fund Structure	Mutual Fund Trust
Subscription	<u>Monthly</u>
Redemption Frequency	Monthly (3 months + 5 business days' notice)
Redemption Gates	7.5% per month, 20% per quarter, 25% per year
Minimum Investment	\$25k initial, \$5k additional
Management Fee <sup>2</sup>	1.65%
Performance Fee <sup>2</sup>	15% over a high-water mark
Fund Codes	BMA80502 (Series F – CAD) BMA80102 (Series F – USD)

#### GROSS PERFORMANCE CONTRIBUTION (since inception)<sup>6</sup>



<b>INCEPTION DATE</b> July 31, 2023 <sup>8</sup>		<b>TOTAL AUM</b> C\$188MM			<b>INVESTMENT TYPE<sup>7</sup></b> 74% Direct <sup>9</sup>			TOTAL INVESTMENTS <sup>1</sup> +1,200		
NET PERFORMANCE <sup>10,11</sup>										
	1M	3M	6M	YTD	1Y	2Y	3Y	Since Inception		
Series F - CAD	0.60%	0.90%	3.42%	3.42%	-	-	-	3.84%		
Series F – USD	0.56%	0.79%	3.17%	3.17%	-	-	_	3.67%		
MSCI World Index	2.27%	3.64%	15.71%	15.71%	_	_	-	20.79%		

#### Hypothetical Growth of C\$100

Growth of C\$ vs. MSCI World Index (since inception)<sup>10,11</sup>



## **Monthly Commentary**


As at June 30, 2024, the net asset value of BMO PG Fund increased from the previous month (0.60% net performance of Series F – CAD), resulting in a performance since inception of 3.84%.

The net asset value of the fund increased in June driven by positive revaluation of the private equity and infrastructure portfolio. The main contributors to private equity performance were direct investments made across 2020-2022, including but not limited to, International Schools Partnership, DiversiTech, and Pharmathen.

For instance, International Schools Partnership (ISP), a leading international K-12schools group providing English and multi-lingual education, is progressing well on its expansion plan and anticipates significant M&A activity in the near term. Partners Group continues to work with ISP's management and board on further building business into a world class learning platform achieving the best student outcomes. ISP has also enjoyed continued organic growth and aims to scale the platform further, developing a unique selling proposition by augmenting education with artificial intelligence (AI) enabled technology.

Over the reporting month, Partners Group agreed to acquire a majority stake in FairJourney Biologics, a leading antibody discovery Contract Research Organization (CRO) based in Porto, Portugal. FairJourney supports pharmaceutical and biotech companies working at the cutting edge of innovation to develop the next generation of antibody-based therapies. The company provides services for the discovery, engineering, production, and characterization of antibodies. FairJourney has demonstrated market leading success rates and outcomes driven by the quality of its people and advanced technologies, supported by state-of-the-art operations in Porto and Cambridge, UK. The company is set to benefit from structural tailwinds driving growth in the market for antibody discovery. This includes higher R&D spending by the pharmaceutical industry, increased outsourcing to specialized innovation partners, the established track record of antibody-based therapies, and a favorable regulatory landscape.

#### Current Portfolio Construction<sup>1</sup>



GROSS PERFORMANCE CONTRIBUTION (by Asset Class) <sup>6</sup>										
	1M	3M	6M	YTD	1Y	2Y	3Y	Since Inception		
Private Equity	0.21%	0.34%	1.40%	1.40%	-	-	-	1.61%		
Infrastructure	0.27%	0.34%	0.69%	0.69%	-	-	-	1.14%		
Real Estate	(0.00%)	0.01%	0.17%	0.17%	-	-	-	(0.69%)		
Private Debt	0.13%	0.23%	1.13%	1.13%	-	-	-	1.69%		
Liquidity	0.02%	0.07%	0.18%	0.18%	-	-	-	0.38%		
Total	0.62%	0.97%	3.56%	3.56%	-	-	-	4.13%		

TOP TEN INVESTMENTS <sup>12</sup>											
Investment	Sector	Country	Investment Date	Investment Type <sup>7</sup>	% of NAV <sup>7</sup>						
Rosen Group	Various	Switzerland	3/27/2024	Direct Private Equity	1.77%						
Alliance Medical Group	Health Care	United Kingdom	1/31/2024	Direct Infrastructure	1.71%						
Heritage Environmental Services	Industrials	USA	3/13/2024	Direct Infrastructure	1.64%						
Galderma	Health Care	Switzerland	10/1/2019	Direct Private Equity	1.45%						
Exus North America	Utilities	USA	10/3/2023	Direct Infrastructure	1.31%						
AlliedUniversal	Industrials	USA	1/31/2020	Direct Private Equity	1.20%						
PCI Pharma Services	Health Care	USA	7/1/2016	Direct Private Equity	1.08%						
Emeria	Real Estate	France	12/10/2021	Direct Private Equity	1.06%						
Ammega (Megadyne - Ammeraal Beltech)	Industrials	Netherlands	7/31/2018	Direct Private Equity	0.97%						
Zabka Polska SA	Consumer Staples	Poland	9/25/2019	Direct Private Equity	0.95%						

# **Net Asset Value & Monthly Performance**

NET ASSET VALUE		
Series F – CAD, NAV per unit	\$103.84	
Series F - USD, NAV per unit	\$103.67	

MONTHLY NET PE	RFORMANC	E <sup>10</sup>											
Year	Jan	Feb	Маг	Apr	May	Jun	Jul	Aug	Sep	0ct	Nov	Dec	Annual
Series F – CAD													
2023	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0.60%	0.24%	(0.29%)	0.55%	(0.69%)	0.41%
2024	0.47%	0.48%	1.53%	0.08%	0.22%	0.60%	n/a	n/a	n/a	n/a	n/a	n/a	3.42%
Series F – USD													
2023	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0.48%	0.28%	(0.64%)	0.79%	(0.41%)	0.49%
2024	0.39%	0.36%	1.59%	(0.18%)	0.40%	0.56%	n/a	n/a	n/a	n/a	n/a	n/a	3.17%

# BMO Partners Group Private Markets Fund Monthly Commentary

### **Disclaimers**

The information contained herein is provided to you for general informational purposes and on the understanding that you accept its inherent limitations, you will not rely on it in making or recommending any investment decision with respect to any securities that may be issued, and you will use it only for the purpose of considering your preliminary interest in investing in a transaction of the type described herein. An investment in the BMO Partners Group Private Markets Fund ("BMO PG Fund") is speculative. A subscription for units of BMO PG Fund should be considered only by persons financially able to maintain their investment and who can bear the risk of loss associated with an investment in BMO PG Fund. Prospective investors should consult with their own independent professional legal, tax, investment and financial advisors before purchasing units of BMO PG Fund in order to determine the appropriateness of this investment in relation to their financial and investment objectives and in relation to the tax consequences of any such investment. Prospective investors should consider the risks described in the confidential offering memorandum (the "OM") of BMO PG Fund before purchasing units of BMO PG Fund. Any or all of these risks, or other as yet unidentified risks, may have a material adverse effect on BMO PG Fund's business and/or the return to investors. See "Investment Objective, Investment Strategy and Certain Risks" in the OM of BMO PG Fund. In addition to the risks described in the OM of BMO PG Fund will bear the risks associated with the Partners Group BMO Master Fund") in proportion to the amount of BMO PG Fund's investment in Master Fund. Prospective investors in BMO PG Fund should therefore carefully consider the risks described under "Certain risk factors", "Business and structure related risks", "Adviser related risks", "Investment-related risks" and "Limits of risk disclosure" in the OM of Master Fund.

The information contained herein does not constitute a solicitation of an offer to buy or sell securities, nor should the information be relied upon as investment advice. Past performance does not guarantee future results.

Statements that depend on future events are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve risks, uncertainties and assumptions. These statements may be based on assumptions that are believed to be reasonable, however there is no assurance that actual results may not differ materially from expectations. Investors should not rely solely on forward-looking statements and should carefully consider the areas of risk described in the most recent offering documents.

BMO Global Asset Management is a brand name under which BMO Asset Management Inc. and BMO Investments Inc. operate. Certain products and services offered under the brand name, BMO Global Asset Management, are designed for specific categories of investors in Canada and may not be available to all investors. Products and services are only offered to investors in Canada in accordance with applicable laws and regulatory requirements.

"BMO (M-bar roundel symbol)" is a registered trademark of Bank of Montreal, used under licence.

<sup>1</sup> BMO Partners Group Private Markets Fund ("BMO PG Fund") achieves its investment objective by investing substantially all of its assets in a diverse portfolio of private markets assets through Partners Group BMO Master Limited ("Master Fund") which holds, directly or indirectly, a portfolio of private markets assets as described in the "Investment Objective" and "Investment Strategy" sections of BMO PG Fund's offering memorandum. Values may not add up due to rounding.

<sup>&</sup>lt;sup>12</sup> The investments listed include BMO PG Fund's exposure to investments under its investment program, some of which were invested in prior to the establishment of BMO PG Fund. See the "Investment Objective" and "Investment Strategy" sections of BMO PG Fund's offering memorandum. Portfolio holdings are subject to change without notice.



<sup>&</sup>lt;sup>2</sup> Management fees correspond to a percentage per annum on the Master Fund shares tracked by the relevant series of units of the BMO PG Fund. Such fees shall be calculated and accrued monthly on the sum of the Master Fund's NAV and the unfunded commitments (without duplication with respect to any cash or liquid investments held pending contributions with respect to any unfunded commitment) made in respect of Master Fund's investments whether held directly or indirectly. Performance fees based on Master Fund NAV.

In the case of the BMO PG Fund, monthly redemptions are available with notice of 3 months (plus 5 business days) prior the relevant dealing day up to redemption gates of 7.5% of the combined NAV of Master Fund Shares per month, 20% of this value per quarter and 25% of this value per year, subject to certain additional potential restrictions and potential issuance of redemption notes in case the redemption gates are exceeded. Subject to certain conditions, redemption payments will generally be made within 45 business days after the relevant dealing day. There is also a 2% early redemption fee in the first two years following the date of a unitholder's initial subscription to the BMO PG Fund. See notably "Summary of Principal Terms" – "Redemptions", "Redemption Gates" and "Early Redemption Fee" of the 0M, "Investment Risks" – "Limited Liquidity on Redemptions" and "Redemption Notes" of the 0M and "General Tax Risks" of the 0M. Redemptions are subject to restrictions described in the 0M for the BMO PG Fund.

<sup>&</sup>lt;sup>4</sup> Registered plan eligibility is subject to the BMO PG Fund meeting certain conditions, see "General Tax Risks" in the OM.

<sup>&</sup>lt;sup>5</sup> Source: Partners Group, as of June 30, 2024.

<sup>&</sup>lt;sup>6</sup> Gross performance contribution is based on BMO PG Fund and excludes all fund fees and expenses incurred as at June 30, 2024.

<sup>&</sup>lt;sup>7</sup> Percentage of NAV of BMO PG Fund as at June 30, 2024.

<sup>&</sup>lt;sup>8</sup> Inception date of July 31, 2023 represents the first trade date of BMO PG Fund and is cited for performance purposes. BMO PG Fund was established on June 22, 2023 by a declaration of trust under the laws of the Province of Ontario.

<sup>&</sup>lt;sup>9</sup> References to "Direct" means investments in companies or physical assets made by Partners Group managed entities. This is different from "Indirect" or "Fund of Fund" investments that invest in other fee-bearing funds.

<sup>&</sup>lt;sup>10</sup> Net performance contribution is based on BMO PG Fund and includes all fund fees and expenses as at June 30, 2024. See the "Terms and Conditions of the Fund" section of BMO PG Fund's offering memorandum for a detailed description of fees and expenses.

<sup>11</sup> The MSCI World Net Total Return Index (CAD) (the "MSCI World Index") is a free float-adjusted market capitalization weighted index that is designed to measure the equity market performance of developed markets and its holdings are not necessarily representative of the holdings of BMO PG Fund, Master Fund and any underlying investments. This index is included as a point of comparison to the net performance contribution of BMO PG Fund because some investors may be significantly allocated to the stock market and may find a comparison to this benchmark to be useful. Source: Bloomberg. Index returns do not reflect transactions costs, or the deduction of other fees and expenses and it is not possible to invest directly in an index. Past performance is not indicative of future results.